The role of the PI3K/Akt/mTOR pathway in glial scar formation following spinal cord injury

Exp Neurol. 2016 Apr:278:27-41. doi: 10.1016/j.expneurol.2016.01.023. Epub 2016 Jan 30.

Abstract

Several studies suggest that glial scars pose as physical and chemical barriers that limit neurite regeneration after spinal cord injury (SCI). Evidences suggest that the activation of the PI3K/Akt/mTOR signaling pathway is involved in glial scar formation. Therefore, inhibition of the PI3K/Akt/mTOR pathway may beneficially attenuate glial scar formation after SCI. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) negatively regulates the PI3K/Akt/mTOR pathway. Therefore, we hypothesized that the overexpression of PTEN in the spinal cord will have beneficial effects after SCI. In the present study, we intrathecally injected a recombinant adenovirus carrying the pten gene (Ad-PTEN) to cause overexpression of PTEN in rats with contusion injured spinal cords. The results suggest overexpression of PTEN in spinal cord attenuated glial scar formation and led to improved locomotor function after SCI. Overexpression of PTEN following SCI attenuated gliosis, affected chondroitin sulfate proteoglycan expression, and improved axon regeneration into the lesion site. Furthermore, we suggest that the activation of the PI3K/Akt/mTOR pathway in astrocytes at 3 days after SCI may be involved in glial scar formation. Because delayed treatment with Ad-PTEN enhanced motor function recovery more significantly than immediate treatment with Ad-PTEN after SCI, the results suggest that the best strategy to attenuate glial scar formation could be to introduce 3 days after SCI. This study's findings thus have positive implications for patients who are unable to receive immediate medical attention after SCI.

Keywords: Astrocyte; Chondroitin sulfate proteoglycans; Glial scar; Phosphatase and tensin homolog deleted on chromosome 10.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cicatrix / etiology*
  • Disease Models, Animal
  • Female
  • Gliosis
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use
  • Locomotion / drug effects
  • Nerve Tissue Proteins / metabolism
  • Neuroglia / pathology*
  • Oncogene Protein v-akt / metabolism
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use
  • Spinal Cord Injuries / complications*
  • Spinal Cord Injuries / pathology*
  • Time Factors

Substances

  • Immunosuppressive Agents
  • Nerve Tissue Proteins
  • Green Fluorescent Proteins
  • Phosphatidylinositol 3-Kinases
  • Oncogene Protein v-akt
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Sirolimus